Posted by Aubrey de Grey, CSO on September 22, 2010 | Founders

This October, Hannover and Detroit will host two of the year's most interesting and wide-ranging scientific conferences in the biomedical field. I'll be chairing sessions at both events, focused on the application of regenerative medicine to aging and aging-related disease - a synergy we at SENS Foundation term rejuvenation biotechnology.

Posted by Michael Rae on September 19, 2010 | Chief Science Officer's Team

The well-known beta-amyloid protein that plays a major role in Alzheimer's disease is only one of those which accumulate in aging bodies. Cardiac amyloidoses, caused by aggregation of the proteins transthyretin and atrial natriuretic peptide, are already the dominant cause of death in supercentenarians (those 110 years of age or older) and are expected to become much more widespread in an increasingly aged general population and as improved treatment options become available for other age-related diseases. SENS Research Foundation has recently launched a project exploring the use of catalytic antibodies - which actively degrade their target, rather than merely binding to it - to remove such aggregates.

Posted by Michael Rae on September 3, 2010 | Chief Science Officer's Team

A technique combining the sequence-specific DNA-cleaving property of zinc finger nucleases (ZFNs) and the localisation function of transcription activator-like effectors (TALEs), creating a new class of composite proteins called TALE nucleases (TALENs), shows considerable promise for expanding the range of genomic sites susceptible to precision engineering.